financetom
Business
financetom
/
Business
/
Eurozone Growth Stalls as Policymakers Show Sense of Urgency, Says ING
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Eurozone Growth Stalls as Policymakers Show Sense of Urgency, Says ING
Jan 30, 2025 4:31 AM

07:12 AM EST, 01/30/2025 (MT Newswires) -- After a few quarters of moderate growth, the eurozone economic recovery has again come to a standstill on Thursday, said ING.

After the energy and inflation shock, the eurozone returned to growth at the start of last year, but 2024 ended back in stagnation mode, wrote the bank in a note.

Growth was negative in France and Germany, with Italy seeing stagnation. Strong growth rates were still seen in Spain and Portugal as Southern Europe remains the bright spot in European economic activity right now, stated ING.

Consumers still seem to be reeling from the inflation shock, as redeemed purchasing power isn't yet translating into a strong consumption recovery. Investment remains under pressure from high inventories in manufacturing, economic uncertainty and high interest rates.

The export environment struggles because of weak external demand. Accoridng to the bank, here's the summary: weakness is all around the eurozone while other major economies show growth.

Policymakers are catching on, added ING. The European Central Bank is set to lower its interest rates by another 0.25 pp later Thursday, and ECB speakers indicate they want to move to a neutral level of interest rates -- where interest rates no longer restrict the economy -- of 2% on the deposit rate quickly.

The bank even thinks that the ECB will go slightly beyond that and lower it to 1.75%.

The European Commission (EC) presented a Competitiveness Compass on Wednesday as President Ursula Von der Leyen took European Union competitiveness as a key objective for her second term. The EC is taking a lot of leaves out of the Mario Draghi playbook to improve productivity, but the big question remains how successful it can be at implementation, asked ING. If successful, it will only boost the economic outlook for the medium term.

For the moment, the economy seems to be in a slump and the bank doesn't expect it to come out of it this winter. The first indications for Q1 are that the economy will hover around stagnation some more.

Over the course of this year, ING predicts domestic demand to drive some economic growth again.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Intel clinches nearly $20 billion in awards from Biden to boost US chip output
Intel clinches nearly $20 billion in awards from Biden to boost US chip output
Mar 20, 2024
WASHINGTON (Reuters) - The Biden administration said it is awarding Intel ( INTC ) nearly $20 billion in grants and loans on Wednesday, supercharging the company's domestic semiconductor chip output and marking the government's largest outlay to subsidize leading-edge chip production. Biden will announce the preliminary agreement for $8.5 billion in grants and up to $11 billion in loans for...
Liquidia Insider Sold Shares Worth $452,183, According to a Recent SEC Filing
Liquidia Insider Sold Shares Worth $452,183, According to a Recent SEC Filing
Mar 20, 2024
05:19 AM EDT, 03/20/2024 (MT Newswires) -- Roger Jeffs, Director, Chief Executive Officer, on March 18, 2024, sold 28,583 shares in Liquidia ( LQDA ) for $452,183. Following the Form 4 filing with the SEC, Jeffs has control over a total of 2,423,607 shares of the company, with 835,345 shares held directly and 1,588,262 shares controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1819576/000110465924036345/xslF345X03/tm247887-3_4seq1.xml...
Adma Biologics Insider Sold Shares Worth $2,803,741, According to a Recent SEC Filing
Adma Biologics Insider Sold Shares Worth $2,803,741, According to a Recent SEC Filing
Mar 20, 2024
05:26 AM EDT, 03/20/2024 (MT Newswires) -- Steve Elms, Director, around March 18, 2024, sold 461,716 shares in Adma Biologics ( ADMA ) for $2,803,741. Following the Form 4 filing with the SEC, Elms has control over a total of 2,192,112 shares of the company, with 76,441 shares held directly and 2,115,671 shares controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1368514/000114036124014226/xslF345X03/form4.xml ...
Aquestive Therapeutics Prices $75 Million Common Stock Offering
Aquestive Therapeutics Prices $75 Million Common Stock Offering
Mar 20, 2024
05:21 AM EDT, 03/20/2024 (MT Newswires) -- Aquestive Therapeutics ( AQST ) said Tuesday it has priced an underwritten public offering of about 16.7 million common shares at $4.50 per share for gross proceeds of about $75 million. Underwriters have been granted a 30-day option to purchase up to 2.5 million additional shares Net proceeds from the offering, which is...
Copyright 2023-2026 - www.financetom.com All Rights Reserved